Alkermes plc. Files 8-K for Regulatory Disclosure

TL;DR

Alkermes filed a routine 8-K, no major news.

AI Summary

Alkermes plc. filed an 8-K on July 21, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing indicates Alkermes is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for regulatory disclosure and does not contain any new material information that would impact risk.

Key Players & Entities

• Alkermes plc. (company) — Registrant
• July 21, 2025 (date) — Date of Report
• Ireland (location) — Jurisdiction of Incorporation

FAQ

From the Filing

0000950170-25-097323.txt : 20250721 0000950170-25-097323.hdr.sgml : 20250721 20250721171635 ACCESSION NUMBER: 0000950170-25-097323 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20250721 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250721 DATE AS OF CHANGE: 20250721 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alkermes plc. CENTRAL INDEX KEY: 0001520262 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 981007018 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35299 FILM NUMBER: 251138059 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 00-353-1-772-8000 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC DATE OF NAME CHANGE: 20110804 FORMER COMPANY: FORMER CONFORMED NAME: Antler Science Two Ltd DATE OF NAME CHANGE: 20110509 8-K 1 alks-20250721.htm 8-K 8-K 0001520262 False Alkermes plc. 0001520262 2025-07-21 2025-07-21     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 21, 2025 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter)   Ireland   001-35299   98-1007018 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)             Connaught House , 1 Burlington Road Dublin 4 , Ireland D04 C5Y6 (Address of principal executive offices)   Registrant's telephone number, including area code: + 353 - 1-772-8000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)       ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)       ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))       ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))     Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Ordinary shares, $0.01 par value   ALKS   Nasdaq Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).       Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         Item 7.01 Regulation FD Disclosure.   On July 21, 2025, Alkermes plc (the “Company”) announced positive topline results from Vibrance-1, a phase 2 study evaluating the safety and efficacy of alixorexton (formerly referred to as ALKS 2680) compared to placebo in patients with narcolepsy type 1. A copy of the press release containing a summary of these topline results is furnished herewith as Exhibit 99.1 and is incorporated herein by ref